

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>WILSON TROY EDWARD</u>  (Last) (First) (Middle) C/O KURA ONCOLOGY, INC. 12730 HIGH BLUFF DRIVE, SUITE 400  (Street) SAN DIEGO CA 92130  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Kura Oncology, Inc. [ KURA ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>President and CEO</b>
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/24/2020</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/24/2020		M <sup>(1)</sup>		6,568	A	\$4.8	34,664	D	
Common Stock	08/24/2020		S <sup>(1)</sup>		6,568	D	\$22.0417 <sup>(2)</sup>	28,096	D	
Common Stock	08/25/2020		M <sup>(1)</sup>		22,838	A	\$6.15	50,934	D	
Common Stock	08/25/2020		M <sup>(1)</sup>		215	A	\$4.8	51,149	D	
Common Stock	08/25/2020		S <sup>(1)</sup>		23,053	D	\$22.374 <sup>(3)</sup>	28,096	D	
Common Stock								1,795,017	I	by Red Fish Blue Fish Revocable Trust
Common Stock								356,736	I	by Araxes Pharma LLC

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Option to purchase common stock	\$4.8	08/24/2020		M <sup>(1)</sup>			6,568	(4)	01/28/2026	Common Stock	6,568	\$0.00	7,160	D	
Option to purchase common stock	\$6.15	08/25/2020		M <sup>(1)</sup>			22,838	(5)	01/22/2027	Common Stock	22,838	\$0.00	211,977	D	
Option to purchase common stock	\$4.8	08/25/2020		M <sup>(1)</sup>			215	(4)	01/28/2026	Common Stock	215	\$0.00	6,945	D	

**Explanation of Responses:**

- The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020.
- This transaction was executed in multiple trades at prices ranging from \$22.00 to \$22.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from \$22.00 to \$22.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This option vested in 48 equal monthly installments commencing on January 29, 2016.
- This option vests in 48 equal monthly installments commencing on January 23, 2017.

**Remarks:**

Marc Grasso, M.D., Attorney-in-fact for Troy E. Wilson 08/26/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**